Trinity Biotech seeks withdrawal of Form F-3 registration

Trinity Biotech plc requests withdrawal of its Registration Statement on Form F-3 (File No. 333-295846), filed May 13, 2026, under Rule 477(a).

Rhea-AI Filing Summary

Trinity Biotech plc requests withdrawal of its Registration Statement on Form F-3 (File No. 333-295846), filed May 13, 2026, under Rule 477(a). The company states it will instead proceed by post-effective amendment to its existing Form F-1 (File No. 333-293717), declared effective March 3, 2026. The F-3 was not declared effective and no securities were issued or sold under it.

Insights

Corporate Securities Counsel

Routine withdrawal to revert to prior registration path.

The company formally requests withdrawal of a Form F-3 registration (File No. 333-295846) filed May 13, 2026, citing intent to proceed by post-effective amendment to its effective Form F-1 declared effective March 3, 2026. The request invokes Rule 477(a).

Practical implications: the withdrawal is procedural while the F-1 remains the operative registration vehicle; timing depends on SEC response, which is typically deemed granted absent a notice within fifteen calendar days.

Key Figures

Form F-3 file number: 333-295846 Form F-1 file number: 333-293717 F-3 filing date: May 13, 2026 +3 more

6 metrics

Form F-3 file number 333-295846 Registration Statement on Form F-3 filed May 13, 2026

Form F-1 file number 333-293717 Existing Registration Statement on Form F-1 declared effective March 3, 2026

F-3 filing date May 13, 2026 Date the Form F-3 registration was filed

F-1 effective date March 3, 2026 Date the underlying Form F-1 was declared effective

SEC response window 15 calendar days Deemed grant period under Rule 477(a)

Securities issued under F-3 0 securities No securities were issued or sold under the Form F-3

Key Terms

Rule 477(a), Form F-3, post-effective amendment

3 terms

Rule 477(a) regulatory

"Pursuant to Rule 477(a) under the Securities Act of 1933"

Form F-3 regulatory

"Registration Statement on Form F-3 (File No. 333-295846)"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

post-effective amendment regulatory

"instead intends to proceed by post-effective amendment to its existing registration statement"

A post-effective amendment is an official update to a securities registration document filed after that document has become effective with regulators; it corrects, adds or replaces information about the securities, the company, or an offering. Investors care because it keeps the legal record current and can change what is being sold or the rights attached to shares — like getting a revised product manual after a launch that may affect value or use.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Trinity Biotech (TRIB) request from the SEC?

Trinity Biotech requested withdrawal of its Form F-3 registration (File No. 333-295846). The company cited Rule 477(a) and plans to proceed by post-effective amendment to its existing Form F-1 declared effective March 3, 2026.

Has Trinity Biotech issued or sold securities under the withdrawn F-3?

No. The company states the Form F-3 was not declared effective and no securities were issued or sold under that registration. The request therefore seeks a procedural withdrawal without any executed sales.

Why is Trinity Biotech withdrawing the Form F-3?

The company states it determined not to proceed with the resale offering on Form F-3 and instead intends to continue by a post-effective amendment to its existing Form F-1, per the explanatory note in the registration documents.

When does the withdrawal become effective?

The company requests effectiveness as of the filing date. Under Rule 477(a), the application is deemed granted as filed unless the SEC notifies the company within fifteen calendar days that the application will not be granted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:23 PM EDT Learn about SEC filing dates

Trinity Biotech plc

IDA Business Park Bray,

County Wicklow,

A98 H5C8 Ireland

VIA EDGAR

June 3, 2026

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E. Washington, D.C. 20549

Attn: Lauren Hamill and Chris Edwards

Re: Trinity Biotech plc

Request for Withdrawal of Registration Statement on Form F-3

File No. 333-295846

Dear Ms. Hamill and Mr. Edwards:

Pursuant to Rule 477(a) under the Securities Act of 1933, as amended, Trinity Biotech plc (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s Registration Statement on Form F-3, together with all exhibits thereto, filed with the Commission on May 13, 2026 (File No. 333-295846) (the “Registration Statement”).

As described in the explanatory note to the Registration Statement, the Registration Statement was filed to convert the Company’s existing effective Registration Statement on Form F-1 (File No. 333-293717), which was declared effective on March 3, 2026, into a Registration Statement on Form F-3 pursuant to Rule 429 under the Securities Act. The Company is seeking withdrawal of the Registration Statement because it has determined not to proceed with the resale offering on Form F-3 and instead intends to proceed by post-effective amendment to its existing registration statement on Form F-1.

The Registration Statement has not been declared effective by the Commission, and no securities have been issued or sold under the Registration Statement.

The Company submits that withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by Rule 477(a). The Company requests that the Commission consent to the withdrawal of the Registration Statement effective as of the date hereof or at the earliest practicable date. It is our understanding that this application for withdrawal will be deemed granted as of the date it is filed with the Commission unless, within fifteen calendar days after such date, the Company receives notice from the Commission that this application will not be granted.

If you have any questions or comments regarding this request, please contact Mary Brown of Carter Ledyard & Milburn LLP at (212) 238-8765.

Very truly yours,

Trinity Biotech plc

By: _/s/ John Gillard___________________

Name: John Gillard

Title: Chief Executive Officer